Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Wages, Salaries and Other
Others
Ratios

Mangoceuticals (MGRX) Non Operating Income (2023 - 2025)

Mangoceuticals' Non Operating Income history spans 3 years, with the latest figure at -$75850.0 for Q3 2025.

  • For Q3 2025, Non Operating Income rose 68.61% year-over-year to -$75850.0; the TTM value through Sep 2025 reached -$480410.0, down 3.47%, while the annual FY2024 figure was -$735233.0, 11458.46% down from the prior year.
  • Non Operating Income for Q3 2025 was -$75850.0 at Mangoceuticals, up from -$147325.0 in the prior quarter.
  • Across five years, Non Operating Income topped out at $13700.0 in Q1 2025 and bottomed at -$270935.0 in Q4 2024.
  • The 3-year median for Non Operating Income is -$111587.5 (2025), against an average of -$117279.4.
  • The largest annual shift saw Non Operating Income tumbled 2804.7% in 2024 before it soared 68.61% in 2025.
  • A 3-year view of Non Operating Income shows it stood at $8233.0 in 2023, then crashed by 3390.84% to -$270935.0 in 2024, then skyrocketed by 72.0% to -$75850.0 in 2025.
  • Per Business Quant, the three most recent readings for MGRX's Non Operating Income are -$75850.0 (Q3 2025), -$147325.0 (Q2 2025), and $13700.0 (Q1 2025).